Archive · 11 Aug 2025
Concord Biotech Stock Dips, Jhunjhunwala Portfolio Sees Impact
Imagine a company called Concord Biotech, which makes medicine.
Its stock price recently went down quite a bit.
This caused the value of shares owned by a famous investor, Rakesh Jhunjhunwala, to decrease by a lot of money.
The company's profits are also down, and its income has gone down too.
The stock has fallen a lot from its highest point, even though it's still worth more than when it first started selling shares.
People are wondering why this is happening.
Concord Biotech shares fell up to 8% on Monday, impacting investor Rakesh Jhunjhunwala's portfolio.
The stock price dropped to Rs 1,479.20, down from its previous close of Rs 1,600.55.
The company's market capitalization decreased below Rs 16,000 crore.
Concord Biotech reported a significant drop in net profit and a decrease in operational revenue.
Jhunjhunwala's stake lost over Rs 300 crore in value due to the stock's decline.
- Who
- Concord Biotech and investor Rakesh Jhunjhunwala
- What
- Concord Biotech's stock price dropped significantly, impacting investor Rakesh Jhunjhunwala's portfolio.
- When
- The stock decline occurred on Monday.
- Where
- India
- Why
- The cause of the stock decline is related to a fall in profit and revenue.
Analysts
Investors
Stock Rating
Analysts
Prior to this, Antique Stock Broking had a target price of Rs 2,110 on the stock with a 'buy' rating
Investors
This is subject to revision post the analysts/investor conference later today.
- Stock Price (Monday)
- Rs 1,479.20
- Previous Close
- Rs 1,600.55
- 52-week high
- Rs 2,658
- Net Profit YoY
- down 30%
- Net Profit Q4FY25
- Rs 41.23 crore
- Jhunjhunwala's Stake Loss
- Rs 305.8 crore
- IPO price
- Rs 741 apeice
- Concord Biotech IPO
- August 2023